Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod

by Vandana Singh, Benzinga Editor

June 18, 2021 1:27 PM | 24 seconds read | Make a Comment

The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's RHHBY Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat System.
This singleplex test is the first real-time RT-PCR test to identify SARS-CoV-2 infection within 20 minutes, both asymptomatic and symptomatic persons.
The test will be available in July.
Price Action: RHHBY shares down 0.75% at $47.14 during the market trading session on the last check Friday.

Posted In: Biotech News Health Care FDA General Briefs Emergency Use Authorization

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.